It is also possible that the temozolomide treatment itself promoted extensive mutation, as recently demonstrated in IDH-mutant low-grade gliomas [44], promoting the escape of resistant clones toward the contralateral hemisphere. This evidence concerns the gene IDH2 and central nervous system cancer.